Cheng-Jung Lai

1.6k total citations
20 papers, 1.3k citations indexed

About

Cheng-Jung Lai is a scholar working on Molecular Biology, Oncology and Genetics. According to data from OpenAlex, Cheng-Jung Lai has authored 20 papers receiving a total of 1.3k indexed citations (citations by other indexed papers that have themselves been cited), including 17 papers in Molecular Biology, 5 papers in Oncology and 4 papers in Genetics. Recurrent topics in Cheng-Jung Lai's work include Histone Deacetylase Inhibitors Research (9 papers), Protein Degradation and Inhibitors (7 papers) and Developmental Biology and Gene Regulation (3 papers). Cheng-Jung Lai is often cited by papers focused on Histone Deacetylase Inhibitors Research (9 papers), Protein Degradation and Inhibitors (7 papers) and Developmental Biology and Gene Regulation (3 papers). Cheng-Jung Lai collaborates with scholars based in United States, France and Australia. Cheng-Jung Lai's co-authors include Xiong Cai, Changgeng Qian, Rudi Bao, Ling Yin, Hai-Xiao Zhai, Hui Qu, Randall T. Moon, Jeffrey Forrester, Philip A. Beachy and Stephen C. Ekker and has published in prestigious journals such as Blood, Development and Cancer Research.

In The Last Decade

Cheng-Jung Lai

20 papers receiving 1.3k citations

Peers

Countries citing papers authored by Cheng-Jung Lai

Since Specialization

Citations

This map shows the geographic impact of Cheng-Jung Lai's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Cheng-Jung Lai with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Cheng-Jung Lai more than expected).

Fields of papers citing papers by Cheng-Jung Lai

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Cheng-Jung Lai. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Cheng-Jung Lai. The network helps show where Cheng-Jung Lai may publish in the future.

Co-authorship network of co-authors of Cheng-Jung Lai

This figure shows the co-authorship network connecting the top 25 collaborators of Cheng-Jung Lai. A scholar is included among the top collaborators of Cheng-Jung Lai based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Cheng-Jung Lai. Cheng-Jung Lai is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	Therapeutic RNA interference: A novel approach to the treatment of primary hyperoxaluria 2021 ·British Journal of Clinical Pharmacology ·Thomas Forbes, Bob D. Brown, Cheng-Jung Lai	25
2	Specific Inhibition of Hepatic Lactate Dehydrogenase Reduces Oxalate Production in Mouse Models of Primary Hyperoxaluria 2018 ·Molecular Therapy ·Cheng-Jung Lai, (unknown), Jessica J. Gierut, Utsav Saxena, Wei Zhou, Michael Dills, Rohan Diwanji, Chaitali Dutta, Martin L. Koser, Naim Nazef, (unknown), Bo Young Kim, Cristina Martín-Higueras, Eduardo Salido, Weimin Wang, Marc Abrams, Henryk Dudek, Bob D. Brown	83
3	Inhibition of Glycogen Synthase II with RNAi Prevents Liver Injury in Mouse Models of Glycogen Storage Diseases 2018 ·Molecular Therapy ·(unknown), Jessica J. Gierut, Wei Zhou, Michael Dills, Rohan Diwanji, Monika Gjorgjieva, Utsav Saxena, Jr-Shiuan Yang, (unknown), (unknown), (unknown), Bo Young Kim, Weimin Wang, Marc Abrams, (unknown), Gilles Mithieux, Fabienne Rajas, Henryk Dudek, Bob D. Brown, Cheng-Jung Lai	22
4	β-Catenin mRNA Silencing and MEK Inhibition Display Synergistic Efficacy in Preclinical Tumor Models 2017 ·Molecular Cancer Therapeutics ·Shanthi Ganesh, (unknown), (unknown), Martin L. Koser, (unknown), (unknown), Cheng-Jung Lai, Henryk Dudek, Weimin Wang, Bob D. Brown, Marc Abrams	18
5	Direct Pharmacological Inhibition of β-Catenin by RNA Interference in Tumors of Diverse Origin 2016 ·Molecular Cancer Therapeutics ·Shanthi Ganesh, Martin L. Koser, (unknown), (unknown), Junyan Tao, (unknown), Bo Ying, Dongyu Chen, (unknown), Edmond Chipumuro, Zakir Siddiquee, (unknown), Cheng-Jung Lai, Henryk Dudek, Satdarshan P. Monga, Weimin Wang, Bob D. Brown, Marc Abrams	50
6	Potential Advantages of CUDC-101, a Multitargeted HDAC, EGFR, and HER2 Inhibitor, in Treating Drug Resistance and Preventing Cancer Cell Migration and Invasion 2013 ·Molecular Cancer Therapeutics ·Jing Wang, (unknown), Maria Samson, Ruzanna Atoyan, Anna Walaszczyk, Abdelkader Selmi, (unknown), Xiong Cai, Maurizio Voi, Pierre Savagner, Cheng-Jung Lai	68
7	Abstract B268: A Phase I Study of CUDC-101, a multitarget inhibitor of HDACs, EGFR, and HER2, in combination with chemoradiation in patients with intermediate/high risk locally advanced squamous cell carcinoma of the head and neck. 2013 ·Molecular Cancer Therapeutics ·Antonio Jimeno, Thomas J. Galloway, Lori J. Wirth, Jill Gilbert, Nabil F. Saba, Julie E. Bauman, Dimitrios Colevas, Ranee Mehra, David Raben, Cheng-Jung Lai, Robert J Laliberte, Maurizio Voi, Barbara Burtness	1
8	CUDC-907, a Dual HDAC and PI3K Inhibitor, Potentially Targets Cancer Cells and The Microenvironment In Hematological Malignancies 2013 ·Blood ·Jing Wang, (unknown), Anna Ma, Ruzanna Atoyan, Maria Samson, Mylissa Borek, Steven DellaRocca, Ling Yin, Da-Gong Wang, Brian Zifcak, Guang-Xin Xu, Maurizio Voi, Cheng-Jung Lai	2
9	A First-In-Man Phase 1 Study Of CUDC-907, a First-In-Class Chemically-Designed Dual Inhibitor Of PI3K and HDAC In Patients With Refractory Or Relapsed Lymphoma and Multiple Myeloma 2013 ·Blood ·Anas Younes, Ian W. Flinn, Yasuhiro Oki, (unknown), Ali Fattaey, Cheng-Jung Lai, Robert J Laliberte, Maurizio Voi, Jesús G. Berdeja	7
10	P057 Micro-RNA expression profiling identifies miR-29b as a relevant pro-fibrogenic factor in Crohn's disease intestinal strictures 2013 ·Journal of Crohn s and Colitis ·Paolo Biancheri, Anke Nijhuis, Antonio Di Sabatino, Cheng-Jung Lai, Arnab Ghosh, Thomas T. MacDonald, Gino Roberto Corazza, (unknown), A. Silver	2
11	Cancer Network Disruption by a Single Molecule Inhibitor Targeting Both Histone Deacetylase Activity and Phosphatidylinositol 3-Kinase Signaling 2012 ·Clinical Cancer Research ·Changgeng Qian, Cheng-Jung Lai, Rudi Bao, Da-Gong Wang, Jing Wang, Guang-Xin Xu, Ruzanna Atoyan, Hui Qu, Ling Yin, Maria Samson, Brian Zifcak, (unknown), Steven DellaRocca, Mylissa Borek, Hai-Xiao Zhai, Xiong Cai, Maurizio Voi	188
12	Abstract 3744: Antitumor activity of CUDC-907, a dual PI3K and HDAC inhibitor, in hematological cancer models 2012 ·Cancer Research ·(unknown), Da-Gong Wang, Hui Qu, Ling Yin, Brian Zifcak, Steven DellaRocca, Guang-Xin Xu, Mylissa Borek, Maria Samson, Ruzanna Atoyan, (unknown), Jing Wang, (unknown), Cheng-Jung Lai, Carmen V. Pepicelli, Xiong Cai, Changgeng Qian	6
13	Abstract 2615: Antitumor activity of a dual PI3K and HDAC inhibitor in hematologic cancer models 2011 ·Cancer Research ·Rudi Bao, Da-Gong Wang, Hui Qu, Ling Yin, Guang-Xin Xu, Steven DellaRocca, Mylissa Borek, Ruzanna Atoyan, Jeffrey Forrester, Maria Samson, Jing Wang, (unknown), (unknown), Cheng-Jung Lai, Xiong Cai, Changgeng Qian	1
14	CUDC-101, a Multitargeted Inhibitor of Histone Deacetylase, Epidermal Growth Factor Receptor, and Human Epidermal Growth Factor Receptor 2, Exerts Potent Anticancer Activity 2010 ·Cancer Research ·Cheng-Jung Lai, Rudi Bao, Xu Tao, Jing Wang, Ruzanna Atoyan, Hui Qu, Da-Gong Wang, Ling Yin, Maria Samson, Jeffrey Forrester, Brian Zifcak, Guang-Xin Xu, Steven DellaRocca, Hai-Xiao Zhai, Xiong Cai, William E. Munger, Mitchell Keegan, Carmen V. Pepicelli, Changgeng Qian	182
15	Discovery of 7-(4-(3-Ethynylphenylamino)-7-methoxyquinazolin-6-yloxy)-N-hydroxyheptanamide (CUDC-101) as a Potent Multi-Acting HDAC, EGFR, and HER2 Inhibitor for the Treatment of Cancer 2010 ·Journal of Medicinal Chemistry ·Xiong Cai, Hai-Xiao Zhai, Jing Wang, Jeffrey Forrester, Hui Qu, Ling Yin, Cheng-Jung Lai, Rudi Bao, Changgeng Qian	218
16	CUDC-305, a Novel Synthetic HSP90 Inhibitor with Unique Pharmacologic Properties for Cancer Therapy 2009 ·Clinical Cancer Research ·Rudi Bao, Cheng-Jung Lai, Hui Qu, Da-Gong Wang, Ling Yin, Brian Zifcak, Ruzanna Atoyan, Jing Wang, Maria Samson, Jeffrey Forrester, Steven DellaRocca, Guang-Xin Xu, Xu Tao, Hai-Xiao Zhai, Xiong Cai, Changgeng Qian	80
17	Targeting heat shock protein 90 with CUDC-305 overcomes erlotinib resistance in non–small cell lung cancer 2009 ·Molecular Cancer Therapeutics ·Rudi Bao, Cheng-Jung Lai, Da-Gong Wang, Hui Qu, Ling Yin, Brian Zifcak, Xu Tao, Jing Wang, Ruzanna Atoyan, Maria Samson, Jeffrey Forrester, Guang-Xin Xu, Steven DellaRocca, Mylissa Borek, Hai-Xiao Zhai, Xiong Cai, Changgeng Qian	47
18	Patterning of the neural ectoderm of Xenopus laevis by the amino-terminal product of hedgehog autoproteolytic cleavage 1995 ·Development ·Cheng-Jung Lai, Stephen C. Ekker, Philip A. Beachy, Randall T. Moon	59
19	Distinct expression and shared activities of members of the hedgehog gene family of Xenopus laevis 1995 ·Development ·Stephen C. Ekker, L. Lynn McGrew, Cheng-Jung Lai, John J. Lee, Doris P. von Kessler, Randall T. Moon, Philip A. Beachy	180
20	Dissecting Wnt signalling pathways and Wnf-sensitive developmental processes through transient misexpression analyses in embryos of Xenopus laevis 1993 ·Development ·Randall T. Moon, Jan L. Christian, Robert M. Campbell, L. Lynn McGrew, Alyce DeMarais, (unknown), Cheng-Jung Lai, Daniel J. Olson, Gregory M. Kelly	47

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact